H. Volkan Kara

Prof. Dr. H. Volkan Kara

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MAMustafa Kemal Arslantas
Mustafa Kemal Arslantas
HKH. Volkan Kara
H. Volkan Kara
BTBeliz Bilgili Tuncer
Beliz Bilgili Tuncer
BYBedrettin Yildizeli
Bedrettin Yildizeli
MYMustafa Yuksel
Mustafa Yuksel
HBHasan F. Batirel
Hasan F. Batirel

12 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MGMustafa Sait Gönen
Mustafa Sait Gönen
MAMerve Alaylıoğlu
Merve Alaylıoğlu
EDEmre Durcan
Emre Durcan
YÖYusuf Özdemir
Yusuf Özdemir
SŞSerdar Şahin
Serdar Şahin
EDErdinç Dursun
Erdinç Dursun
Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

1 July 2006 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
SDS. Ibrahim Dincer
S. Ibrahim Dincer
ADAdalet Demir
Adalet Demir
ASAdnan Sayar
Adnan Sayar
MGM. Zeki Gunluoglu
M. Zeki Gunluoglu
HKH. Volkan Kara
H. Volkan Kara
AGAtilla Gurses
Atilla Gurses

27 November 2018 in Libyan Journal of Medicine
Verified
Journal Article
Open access
ÖEÖncü Koç Erbaşoğlu
Öncü Koç Erbaşoğlu
CHCem Horozoğlu
Cem Horozoğlu
ŞEŞeyda Ercan
Şeyda Ercan
HKH. Volkan Kara
H. Volkan Kara
ATAkif Turna
Akif Turna
IYIlhan Yaylim
Ilhan Yaylim
It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor related apoptosis inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease. In this study, TRAIL C1595T polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis in 158 patients with NSCLC and 98 healthy individuals. Surgically resected tissues were examined and classified histopathologically. In addition, TRAIL gene expression levels in tumor tissue and tumor surrounding tissue samples of 48 patients with NSCLC were determined using real-time polymerase chain reaction. TRAIL gene expression levels of NSCLC patients were detected significantly 28.8 fold decrease in the tumor tissue group compared to the control group (p=0.026). When patients were compared to tumor stage, expression of TRAIL gene in advanced tumor stage was found to be significantly 7.86 fold higher than early tumor stage [p=0.028]. No significant relationship was found between NSCLC predisposition and prognostic parameters of NSCLC with TRAIL genotypes, but the frequency of TRAIL gene 1595 CT genotype was observed to be lower in the patients compared to the other genotypes, and the difference was found to be very close to statistical significance (p=0.07). It can be suggested that TRAIL may play an important role in the development of NSCLC and may be an effective prognostic factor in tumor progression.: It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease.

1 February 2018 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ATAkif Turna
Akif Turna
HMHüseyin Melek
Hüseyin Melek
HKH. Volkan Kara
H. Volkan Kara
BKBurcu Kılıç
Burcu Kılıç
EEEzel Erşen
Ezel Erşen
KKKamil Kaynak
Kamil Kaynak

1 December 2014 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HKH. Volkan Kara
H. Volkan Kara
SBStafford S. Balderson
Stafford S. Balderson
TDThomas A. D’aMico
Thomas A. D’aMico